Table 4.
Clinical trials investigating immune checkpoint inhibitors in malignant pleural mesothelioma pretreated population
| Study | Phase | Agent(s) | n | ORR (%) | mPFS (months) | mOS (months) |
|---|---|---|---|---|---|---|
| KN028 | Ib | Pembrolizumab | 25 (PD-L1+) | 20 | 5.4 | 18 |
| JAVELIN | Ib | Avelumab | 53 | 9 | 4.1 | 10.7 |
| Treme (Italy) | II | Tremelimumab | 29 | 14 | 6.2 | 11.3 |
| MERIT | II | Nivolumab | 34 | 29 | 6.1 | 17.3 |
| Pembrolizumab (Chicago) | II | Pembrolizumab | 64 | 22 | 4.1 | 11.5 |
| NIBIT-Meso1 | II | Tremelimumab/durvalumab | 40 (30% 1L) | 28 | 5.7 | 16.6 |
| INITIATE | II | Nivolumab/ipilimumab | 34 | 29 | NR (>6.2) | NR (>12.7) |
| MAPS2 | II | Nivolumab versus nivolumab/ipilimumab | 63 and 62 | 19 and 28 | 4 and 5.6 | 11.9 and 15.9 |
| DETERMINE | IIb | Tremelimumab versus placebo | 571 | 4.5 | 2.8 | 7.7 |
| PROMISE-Meso | III | Pembrolizumab versus chemotherapy | 144 | 22 | 2.5 | 10.7 |
| CONFIRM | III | Nivolumab versus placebo | 332 | 10.4 | 3 | 9.2 |
| DIADEM | II | Durvalumab | 69 | 10.3 | 2 | 7.3 |
1L, first line; mOS, median overall survival; mPFS, median progression-free survival; n, number of patients enrolled; NR, not reached; ORR, objective response rate.